Meta-signature of mutated genes in gallbladder cancer: evidence based high throughput screening assays

Gallbladder carcinoma (GBC) is the fifth most common carcinoma of gastrointestinal tract, and represents 80–95% of biliary tract cancers. It is relatively an uncommon malignant disease with a poor prognosis. According to previous reports (1), GBC has a low incidence rate (<2/100,000). Reid et al. (2) found that the worldwide incidence of GBC correlates with the prevalence of gallstone disease. The high-incidence areas of GBC are Poland (14/100,000), Northern India (21.5/100,000), south Pakistan (11.3/100,000), Israel (5/100,000) and Japan (7/100,000) (1). Besides, GBC is more common in females. Stinton et al. (1) demonstrated that the incidence rate was high in South American females, 15.5 per 100,000 in Bolivia (vs. 7.5/100,000 in male), and 11.3 per 100,000 in New Mexico (vs. 4/100,000 in male).